Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALX-0600 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | placebo solution injected subcutaneously daily into either thigh or abdomen. |
| teduglutide 0.05 | EXPERIMENTAL | teduglutide 0.05 mg/kg/d injected subcutaneously daily. |
| teduglutide 0.1 | EXPERIMENTAL | 0.1 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen |
| teduglutide | EXPERIMENTAL | 0.2 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen |
| Name | Type | Description |
|---|---|---|
| ALX-0600 | DRUG | teduglutide |
| placebo | DRUG | placebo solution injected subcutaneously |
| teduglutide 0.05 | DRUG | 0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen |
| teduglutide 0.2 mg | DRUG | 0.2 mg/kg/d subcutaneously injected into thigh or abdomen |
| Teduglutide 0.05 dose | DRUG | 0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen |
| teduglutide 0.1 mg dose | DRUG | 0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen |
Inclusion Criteria 1. Men and women, 18 years of age and older 2. Signed and dated informed consent to participate before any study-related procedures are performed 3. Diagnosis of Crohn's disease for at least 6 months that has been documented and confirmed 4. A Crohn's Disease Activity Index (CDAI...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
ALX-0600 is an investigational small molecule being studied for the treatment of active Crohn's Disease. It has been evaluated in a Phase 2 clinical trial to assess its safety and efficacy in patients with this condition. The drug is not approved and remains in clinical development.
ALX-0600 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting clinical research on this investigational drug for Crohn's Disease.
ALX-0600 is in Phase 2 clinical development. It has completed a Phase 2 trial for active Crohn's Disease, but it is not FDA approved and remains an investigational drug.
ALX-0600 has been studied in one completed Phase 2 clinical trial, identified as NCT00072839. This trial, titled 'Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease,' enrolled 100 participants in the United States and Canada.
Yes, ALX-0600 is a small molecule drug. It is being developed as an oral treatment for Crohn's Disease, a gastrointestinal condition. The drug is currently in Phase 2 clinical testing.